The value of 4-month neurocognitive function as an endpoint in brain metastases trials.

Item

http://www.wikidata.org/entity/Q44325965

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh-hant

name

The value of 4-month neurocognitive function as an endpoint in brain metastases trials.

@en

The value of 4-month neurocognitive function as an endpoint in brain metastases trials.

@nl

type

Item

label

The value of 4-month neurocognitive function as an endpoint in brain metastases trials.

@en

The value of 4-month neurocognitive function as an endpoint in brain metastases trials.

@nl

prefLabel

The value of 4-month neurocognitive function as an endpoint in brain metastases trials.

@en

The value of 4-month neurocognitive function as an endpoint in brain metastases trials.

@nl

P1476

The value of 4-month neurocognitive function as an endpoint in brain metastases trials

@en

P2093

Atsuhito Toyomaki

http://www.w3.org/2001/XMLSchema#string

Hiroki Shirato

http://www.w3.org/2001/XMLSchema#string

Khin Khin Tha

http://www.w3.org/2001/XMLSchema#string

Naoki Hashimoto

http://www.w3.org/2001/XMLSchema#string

Satoshi Terae

http://www.w3.org/2001/XMLSchema#string

Shunsuke Onodera

http://www.w3.org/2001/XMLSchema#string

P2860

Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group.

Effect of age and education on the Trail Making Test and determination of normative data for Japanese elderly people: the Tajiri Project.

The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity.

Phase III trial of prophylactic cranial irradiation compared with observation in patients with locally advanced non-small-cell lung cancer: neurocognitive and quality-of-life analysis.

Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study.

Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases.

Diffusion tensor imaging of normal-appearing white matter as biomarker for radiation-induced late delayed cognitive decline.

Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial.

Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group.

Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial.

P2888

s11060-014-1550-y

P304

311-319

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11060-014-1550-Y

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

120

http://www.w3.org/2001/XMLSchema#string

P50

Hidefumi Aoyama

P577

2014-07-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

264055284

http://www.w3.org/2001/XMLSchema#string

P698

25037611

http://www.w3.org/2001/XMLSchema#string